Clinical Trial Update: Comparative Bioavailability Study of BIA 9-1067 25 mg Capsules [Phase 1]

View source ↗

Summary

Phase 1 comparative bioavailability study of BIA 9-1067 25 mg capsules in Parkinson's disease; the study has completed and results were posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• BIA 9-1067

Snippet

Sponsor: Bial - Portela C S.A. | Conditions: Parkinson | Phase 1 | Status: COMPLETED | Results posted: 2015-01-09